LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Lantheus Holdings Inc

Cerrado

SectorSalud

56.71 2.03

Resumen

Variación precio

24h

Actual

Mínimo

55

Máximo

56.94

Métricas clave

By Trading Economics

Ingresos

5.8M

79M

Ventas

5.3M

378M

P/B

Media del Sector

14.936

35.724

Margen de beneficio

20.832

Empleados

808

EBITDA

7.7M

123M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+54.74% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.1B

3.8B

Apertura anterior

54.68

Cierre anterior

56.71

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

44 / 372 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Lantheus Holdings Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 ago 2025, 22:51 UTC

Ganancias

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 ago 2025, 23:57 UTC

Ganancias

Trip.com Group 1H Rev $4.01B

27 ago 2025, 23:57 UTC

Ganancias

Trip.com Group 1H Adj EPS $1.84

27 ago 2025, 23:57 UTC

Ganancias

Trip.com Group 1H EPS $1.82

27 ago 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 ago 2025, 23:39 UTC

Ganancias

Correction to Nvidia Earnings Article -- WSJ

27 ago 2025, 22:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 ago 2025, 22:59 UTC

Charlas de Mercado

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 ago 2025, 22:58 UTC

Ganancias

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 ago 2025, 22:57 UTC

Ganancias

South32 FY Free Cash Flow $192 Million

27 ago 2025, 22:56 UTC

Ganancias

South32 FY Total Capital Expenditure $1.35 Billion

27 ago 2025, 22:56 UTC

Ganancias

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 ago 2025, 22:55 UTC

Ganancias

South32 Net Cash $123 Million at June 30

27 ago 2025, 22:54 UTC

Ganancias

South32: Focused on Maintaining Strong Operating Momentum

27 ago 2025, 22:53 UTC

Ganancias

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 ago 2025, 22:53 UTC

Ganancias

South32 Extends Capital Management Program for 12 Months

27 ago 2025, 22:52 UTC

Ganancias

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 ago 2025, 22:51 UTC

Ganancias

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 ago 2025, 22:51 UTC

Ganancias

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 ago 2025, 22:50 UTC

Ganancias

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 ago 2025, 22:50 UTC

Ganancias

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 ago 2025, 22:45 UTC

Ganancias

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 ago 2025, 22:44 UTC

Ganancias

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 ago 2025, 22:44 UTC

Ganancias

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 ago 2025, 22:43 UTC

Ganancias

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 ago 2025, 22:43 UTC

Ganancias

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 ago 2025, 22:42 UTC

Ganancias

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 ago 2025, 22:42 UTC

Ganancias

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 ago 2025, 22:40 UTC

Ganancias

Sandfire Resources Net Debt $123 Million at June 30

27 ago 2025, 22:40 UTC

Ganancias

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparación entre iguales

Cambio de precio

Lantheus Holdings Inc Esperado

Precio Objetivo

By TipRanks

54.74% repunte

Estimación a 12 meses

Media 86.13 USD  54.74%

Máximo 110 USD

Mínimo 63 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lantheus Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

7

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

79.24 / 103.64Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

44 / 372 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.